Cerenis Therapeutics, Inc. Featured Prominently At The 25th Conference Of The Asian Pacific Association For The Study Of The Liver (APASL)

TOULOUSE, France & ANN ARBOR, Mich.--(BUSINESS WIRE)--Cerenis Therapeutics (FR0012616852- CEREN) (Paris:CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, today reported two poster presentations featuring Cerenis Therapeutics’ innovative HDL therapy, CER-209, during the 25th Conference of the APASL held in Tokyo, February 20-24, 2016.